Big Partnerships Give Biotechs A Boost To Richer Exits
This article was originally published in Start Up
Biotechs in recent years are more likely to fetch a higher acquisition price – practically the only way for investors to exit these days – if the company has previously signed a major alliance. But the partners aren't necessarily the ones buying.
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.